Brazil’s Anvisa rejects bid to import Bharat Biotech vaccine

The Brazilian government signed a contract last month to buy 20 million doses of Covaxin, and Bharat Biotech applied for emergency use of the vaccine in Brazil on March 8.

RIO DE JANEIRO, BRAZIL - Brazilian health regulator Anvisa on Wednesday, March 31,  rejected a request from the government to import doses of Covaxin, the COVID-19 vaccine developed by Indian laboratory Bharat Biotech, citing a lack of safety data and documentation.

“The importer did not present all the documents required by law,” said Anvisa board member Alex Machado Campos.

The Brazilian government signed a contract last month to buy 20 million doses of Covaxin and Bharat Biotech applied for emergency use of the vaccine in Brazil on March 8.

However, Anvisa said the vaccine did not meet its manufacturing standards . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?